cas 1023742-13-3|| where to buy O-[2-[(2-methylpropan-2-yl)oxy]ethyl]hydroxylamine

Nombre del producto:O-[2-[(2-methylpropan-2-yl)oxy]ethyl]hydroxylamine

IUPAC Name:O-[2-(tert-butoxy)ethyl]hydroxylamine

Unidad de embalaje	Stock disponible	Precio($)
CM325604-100g	in stock	ŗŗľ
CM325604-500g	in stock	Ĳƿƥŗ

Sólo para uso en I+D..

Formulario de consulta

Nombre químico

Número CAS

Cantidad*

Especificaciones requeridas*
(% de ensayo, grado de material, etc.)

Nombre de contacto*

Correo electrónico de contacto*

Meanwhile I'd like to create a registered account on CHEMENU.COM with the above email.

I'd like to receive emails related to products with similar structures to 1023742-13-3 regularly via the above email.

Notas adicionales

Verification code*

refresh

: Núm. De CAS :1023742-13-3; Fórmula molecular:C6H15NO2; Punto de fusión:-; Código de sonrisas:NOCCOC(C)(C)C; Densidad:

: Número de catálogo:CM325604; Peso molecular:133.19; Punto de ebullición:; Nº Mdl:; Almacenamiento:

: Aliphatic Chain Compounds; Aliphatic chain compounds include aliphatic compounds and chain compounds containing other elements or groups. Aliphatic hydrocarbons are hydrocarbons with the basic properties of aliphatic compounds. In aliphatic compounds, carbon atoms are arranged in straight chain, branched chain or cyclic, which are respectively called straight chain aliphatic hydrocarbons, branched chain aliphatic hydrocarbons and alicyclic hydrocarbons. Some cyclic hydrocarbons are different in nature from aromatic hydrocarbons, and are very similar to aliphatic hydrocarbons. Such cyclic hydrocarbons are called alicyclic hydrocarbons. In this way, aliphatic hydrocarbons become a general term for all hydrocarbons except aromatic hydrocarbons. Aliphatic hydrocarbons and their derivatives (including halogenated hydrocarbons) and alicyclic hydrocarbons and their derivatives are collectively referred to as aliphatic compounds.

: Encorafenib plus Binimetinib; U.S. FDA approved Pfizer's BRAFTOVI® (Encorafenib) + MEKTOVI® (Binimetinib) for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) with a BRAF V600E mutation. The FDA's approval is based on data from the ongoing Phase 2 PHAROS clinical trial. Encorafenib is an oral small molecule BRAF kinase inhibitor, and Binimetinib is an oral small molecule MEK inhibitor targeting key proteins in the MAPK signaling pathway (RAS-RAF-MEK-ERK).
Chemenu has been working to develop more compounds for drug discovery. Here are the building blocks we can provide.